- Home
- LUXE vs AVBP Comparison
LUXE vs AVBP Comparison
Compare LUXE & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUXE
- AVBP
- Stock Information
- Founded
- LUXE 1987
- AVBP 2021
- Country
- LUXE Germany
- AVBP United States
- Employees
- LUXE N/A
- AVBP N/A
- Industry
- LUXE
- AVBP
- Sector
- LUXE
- AVBP
- Exchange
- LUXE NYSE
- AVBP NYSE
- Market Cap
- LUXE 1.0B
- AVBP 862.8M
- IPO Year
- LUXE N/A
- AVBP 2024
- Fundamental
- Price
- LUXE $7.82
- AVBP $20.77
- Analyst Decision
- LUXE
- AVBP Strong Buy
- Analyst Count
- LUXE 0
- AVBP 8
- Target Price
- LUXE N/A
- AVBP $39.00
- AVG Volume (30 Days)
- LUXE 120.4K
- AVBP 487.8K
- Earning Date
- LUXE 05-14-2025
- AVBP 08-13-2025
- Dividend Yield
- LUXE N/A
- AVBP N/A
- EPS Growth
- LUXE N/A
- AVBP N/A
- EPS
- LUXE N/A
- AVBP N/A
- Revenue
- LUXE $962,367,055.00
- AVBP N/A
- Revenue This Year
- LUXE $38.43
- AVBP $85.82
- Revenue Next Year
- LUXE $93.30
- AVBP N/A
- P/E Ratio
- LUXE N/A
- AVBP N/A
- Revenue Growth
- LUXE 8.74
- AVBP N/A
- 52 Week Low
- LUXE $3.22
- AVBP $15.47
- 52 Week High
- LUXE $12.50
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- LUXE N/A
- AVBP 39.60
- Support Level
- LUXE N/A
- AVBP $20.00
- Resistance Level
- LUXE N/A
- AVBP $23.27
- Average True Range (ATR)
- LUXE 0.00
- AVBP 1.51
- MACD
- LUXE 0.00
- AVBP -0.49
- Stochastic Oscillator
- LUXE 0.00
- AVBP 13.28
About LUXE LUXEXPERIENCE B.V. SPON ADS EACH RE SPON ADS EACH REP 1 ORD SHS
LuxExperience BV is the digital, multi-brand luxury group and the online shopping destination for luxury enthusiasts. The group operates a portfolio of some of the distinguished store brands in digital luxury and creates communities for luxury enthusiasts with digital and physical experiences. Its brands are MYTHERESA, NET-A-PORTER, MR PORTER, YOOX, and THE OUTNET.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.